Polyrizon Ltd. Completes FDA Pre-Submission Meeting for Allergy Blocker
Ticker: PLRZ · Form: 6-K · Filed: Dec 8, 2025 · CIK: 1893645
| Field | Detail |
|---|---|
| Company | Polyrizon Ltd. (PLRZ) |
| Form Type | 6-K |
| Filed Date | Dec 8, 2025 |
| Risk Level | medium |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: regulatory-filing, medical-device, fda
TL;DR
Polyrizon met with FDA on Dec 8 for allergy nasal spray PL-14. Big step for market approval.
AI Summary
Polyrizon Ltd. announced on December 8, 2025, that it has completed a Pre-Submission meeting with the U.S. Food and Drug Administration (FDA) regarding its PL-14 Allergy Blocker Nasal Spray. This meeting is a significant step in the regulatory process for the product. The company is based in Raanana, Israel.
Why It Matters
This FDA pre-submission meeting is a crucial step towards potential market approval for Polyrizon's PL-14 Allergy Blocker, impacting the future availability of this new allergy treatment.
Risk Assessment
Risk Level: medium — Regulatory processes with the FDA are complex and carry inherent risks of delays or non-approval, which can significantly impact a company's prospects.
Key Players & Entities
- Polyrizon Ltd. (company) — Filer of the report and developer of PL-14
- PL-14 Allergy Blocker Nasal Spray (product) — Product undergoing FDA review
- U.S. Food and Drug Administration (FDA) (company) — Regulatory body met with by Polyrizon
- December 8, 2025 (date) — Date of the FDA pre-submission meeting and press release
FAQ
What was the purpose of the FDA Pre-Submission meeting for Polyrizon Ltd.'s PL-14 Allergy Blocker Nasal Spray?
The purpose was to discuss the regulatory pathway and requirements for the PL-14 Allergy Blocker Nasal Spray with the FDA.
When did Polyrizon Ltd. announce the completion of this FDA meeting?
Polyrizon Ltd. announced the completion of the FDA pre-submission meeting on December 8, 2025.
What is the product Polyrizon Ltd. is seeking FDA feedback on?
The product is the PL-14 Allergy Blocker Nasal Spray.
What form is Polyrizon Ltd. required to file as a foreign private issuer?
Polyrizon Ltd. files as a foreign private issuer and indicates it files annual reports under cover of Form 20-F.
Where is Polyrizon Ltd. located?
Polyrizon Ltd.'s principal executive offices are located at 5 Ha-Tidhar Street, Raanana, 4366507, Israel.
Filing Stats: 259 words · 1 min read · ~1 pages · Grade level 12.8 · Accepted 2025-12-08 09:00:01
Filing Documents
- ea0268809-6k_polyrizon.htm (6-K) — 10KB
- ea026880902ex99-1_polyrizon.htm (EX-99.1) — 11KB
- 0001213900-25-118981.txt ( ) — 23KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Polyrizon Ltd. Date: December 8, 2025 By: /s/ Tomer Izraeli Name: Tomer Izraeli Title: Chief Executive Officer 3